NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare
Under the agreement, NascaCell grants GE Healthcare the exclusive rights to distribute its aptamers in Japan for target validation and drug discovery applications. GE Healthcare will initiate and negotiate agreements with prospective customers for aptamers and related services.
"We are delighted to work together with GE Healthcare to grow the market for aptamers. Because of its excellent recognition and network, GE Healthcare is our first choice as a partner," said Andreas Jenne, Ph.D., NascaCell's co-founder and chief executive officer.
Aptamers are synthetic drug-like molecules that can specifically knock-down protein functions in cells and organisms. Their rapid production and convenient handling mean aptamers can be used in numerous drug discovery applications, such as animal studies or high throughput drug screening (HTS).
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.